Actavis rescues Allergan with $66 billion deal
Deal ends takeover fight with Valeant – but Actavis must still be ‘fairly ruthless’ to justify the high price
To continue reading this article
You need to sign in or choose one of these options
Subscribe
£36 annual | Pay monthly | Pass
Subscribers get unlimited access to Chemistry World. No more paywalls. Plus your subscription will help fund the charitable work of the Royal Society of Chemistry, supporting chemists worldwide.
Register
Free
You'll be able to read more articles each month before you see another paywall. Perfect if you're a light user or want to read more before deciding to subscribe. It takes less than a minute and it's completely free.
Membership
Included as a benefit
Members of the Royal Society of Chemistry have unlimited access to Chemistry World as a benefit of membership. Just sign in with your usual membership credentials. Not a member? Find out how to join.